HRAS and breast cancer: Notably, only 6.5% of OSCC patients harbored at least one PIK3CA and HRAS mutation, whereas, these oncogenic mutations occur in 30-70% of solid tumours, including colorectal, ovarian, endometrial, lung, melanoma and breast cancer (Table S8 in File S1) [22,34].